Background::The efficacy of entecavir (ETV) add-on peg-interferon therapy compared with ETV monotherapy in treatment-na?ve hepatitis B virus (HBV) patients remains controversial. We investigated whether adding peg-interferon to ongoing ETV treatment leads to a better curative effect or not.Methods::All patients have been recruited between August 2013 and January 2015 from the Shanghai Public Health Clinical Center and Zhongshan Hospital (China). Eligible HBV patients ( n = 144) were randomly divided (1:1) to receive either ETV monotherapy ( n = 70) or peg-interferon add-on therapy from week 26 to 52 ( n = 74). Patients were followed-up for at least 2 years. Indexes including hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) seroconversion rate, sustained virologic response, transient elastography value, and histological scores were evaluated every 3 months until the end of the study. The rate of patients with HBsAg loss was defined as the primary endpoint criteria. R

作者：Yang Jing-Mao；Chen Li-Ping；Wang Ya-Jie；Lyu Bei；Zhao Hong；Shang Zhi-Yin；Li Jun；Fan Zhen-Yu；Wu Sheng-Di；Ming Xiao；Li Xian；Huang Shao-Ping；Cheng Ji-Lin

来源：中华医学杂志英文版 2020 年 133卷 14期